Fucoidin solid beverage capable of preventing helicobacter pylori infection and preparation method of fucoidin solid beverage

Abstract

The invention discloses a fucoidin solid beverage capable of preventing helicobacter pylori infection and a preparation method of the fucoidin solid beverage, and belongs to the technical field of marine organism polysaccharide preparation. The solid beverage takes fucoidin as a main raw material and is compounded with whey protein, resistant dextrin and vitamin B12. The fucoidin mainly comprises fucose, and also contains a small amount of galactose, mannose, glucuronic acid and xylose in a molar ratio of 57: 7.0: 7.0: 15: 15 (mol%), and the molecular weight of the fucoidin is about 40 kDa. The fucoidin solid beverage provided by the invention can improve stomach inflammation and helicobacter pylori colonization amount in a helicobacter pylori infection process, and has a prevention effect on helicobacter pylori infection.

Description

Technical Field

[0001] The present invention belongs to the technical field of marine biopolysaccharide preparation, and in particular relates to a fucoidan solid beverage capable of preventing Helicobacter pylori infection and a preparation method thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance understanding of the overall background of the invention and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to those skilled in the art.

[0003] Helicobacter pylori, also known as H. pylori, is a microaerophilic Gram-positive bacillus that widely colonizes the gastric mucosa and can induce chronic gastritis, peptic ulcers, and gastric cancer. The global infection rate for H. pylori is approximately 50%, with an average infection rate among children as high as 40%, and is increasing at a rate of 0.5%-1% per year. It is reported that almost all H. pylori-infected individuals will develop gastritis, primarily affecting the corpus and antrum, or pangastritis. 15%-20% of H. pylori-infected individuals will develop peptic ulcers. Furthermore, H. pylori-infected individuals have a higher risk of developing gastric cancer and mucosa-associated lymphoid tissue lymphoma compared to uninfected individuals. Currently, the traditional treatment for H. pylori is quadruple therapy, but long-term use can rapidly increase drug resistance in H. pylori and can also produce serious toxic side effects.

[0004] In recent years, the inhibitory activity of fucoidan against Helicobacter pylori has become a research hotspot. Fucoidan has the ability to eliminate H. pylori and effectively prevent its adhesion to gastric epithelial cells. It can also correct the imbalance of intestinal flora caused by standard quadruple therapy, protect the gastric mucosa, and inhibit gastric inflammation. The development of functional health foods based on fucoidan, combined with whey protein powder and dietary fiber, that can prevent H. pylori infection, protect the stomach, and have minimal toxic side effects has important practical significance for combating H. pylori infection. Summary of the Invention

[0005] In order to solve the above problems, the purpose of the present invention is to provide a fucoidan solid beverage that can prevent Helicobacter pylori infection and a preparation method thereof. The fucoidan solid beverage provided by the present invention can reduce the gastric inflammatory response and the amount of Helicobacter pylori colonization during Helicobacter pylori infection in the body, that is, the fucoidan solid beverage obtained by the present invention has a preventive effect on Helicobacter pylori infection.

[0006] In order to achieve the above object, the technical solution of the present invention is: The first aspect of the present invention provides a fucoidan solid beverage having the function of preventing Helicobacter pylori infection, comprising fucoidan, whey protein, resistant dextrin and vitamin B12; The fucoidan comprises fucose, galactose, mannose, glucuronic acid, and xylose in a molar ratio of 57:7.0:7.0:15:15, mol%, and a molecular weight of 38-42 kDa. The solid beverage can improve gastric inflammation and Helicobacter pylori colonization during Helicobacter pylori infection.

[0007] The second aspect of the present invention provides a method for preparing the above-mentioned fucoidan solid beverage capable of preventing Helicobacter pylori infection, comprising: S1. After degreasing the brown algae powder with 10-15 times the volume of ethanol solution, the precipitate was collected and dried; S2. Add 1.5%-2.5% CaCl2 solution to the defatted brown algae powder, stir at 60°C for 2-3 hours, separate the solid and liquid, collect the supernatant, concentrate the supernatant, precipitate with alcohol, and collect the precipitate to obtain fucoidan; The material-liquid ratio of brown algae powder to CaCl2 solution is 1 g:10-20 mL; S3. Mix the raw materials according to the weight ratio of 3 parts of fucoidan, 1 part of resistant dextrin, 1 part of whey protein powder, and 0.000006% of vitamin B12, redissolve and homogenize, then spray-dry and directly bag to obtain a fucoidan solid beverage.

[0008] The third aspect of the present invention provides a use of the above-mentioned fucoidan solid beverage or the fucoidan solid beverage prepared by the above-mentioned preparation method in the preparation of products for preventing and / or treating Helicobacter pylori infection.

[0009] The beneficial effects of the present invention are: (1) It can reduce the gastric inflammatory response and the amount of Helicobacter pylori colonization during Helicobacter pylori infection in the body, that is, the fucoidan solid beverage obtained by the present invention has a preventive effect on Helicobacter pylori infection.

[0010] (2) The preparation method of the present invention is simple, practical, and easy to promote. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] The accompanying drawings, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0012] Figure 1 This is a HE staining scoring diagram of mouse gastric tissue after intervention with fucoidan according to Example 1 of the present invention; Figure 2 This is a Giemsa staining scoring diagram of mouse gastric tissue after fucoidan intervention in Example 1 of the present invention. DETAILED DESCRIPTION

[0013] It should be noted that the following detailed descriptions are exemplary and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0014] Currently, Helicobacter pylori infection rates are high and it is recognized as a risk factor for gastric diseases. The market for functional foods designed to prevent and treat H. pylori is enormous. Research has shown that fucoidan can eliminate H. pylori and effectively prevent its adhesion to gastric epithelial cells. It can also correct the imbalance of intestinal flora caused by standard quadruple therapy, protect the gastric mucosa, and inhibit gastric inflammation. The development of functional health foods based on fucoidan, combined with whey protein powder and dietary fiber, that can prevent H. pylori infection, protect the stomach, and have minimal toxic side effects has important practical significance for combating H. pylori infection.

[0015] In view of this, the present invention proposes a fucoidan solid beverage that can prevent Helicobacter pylori infection.

[0016] A typical embodiment of the present invention provides a fucoidan solid beverage with the ability to prevent Helicobacter pylori infection. This solid beverage uses fucoidan as the main ingredient and is compounded with whey protein, resistant dextrin, and vitamin B12. The fucoidan is primarily composed of fucose, and also contains small amounts of galactose, mannose, glucuronic acid, and xylose in a molar ratio of 57:7.0:7.0:15:15 (mol%), with a molecular weight of approximately 40 kDa. This solid beverage can improve gastric inflammation and H. pylori colonization during H. pylori infection, thus having a preventive effect on H. pylori infection.

[0017] Another typical embodiment of the present invention provides a method for preparing a fucoidan solid beverage capable of preventing Helicobacter pylori infection, comprising: S1. After defatting the brown algae powder, collecting the precipitate and drying it; S2. Add CaCl2 solution to the defatted brown algae powder, stir for a set time, separate the solid and liquid, collect the supernatant, concentrate the supernatant, precipitate with alcohol, and collect the precipitate to obtain fucoidan; S3. According to the weight ratio, 3 parts of fucoidan, 1 part of resistant dextrin, 1 part of whey protein powder, and 0.000006% of vitamin B12 are mixed, redissolved, homogenized, spray-dried, and directly bagged to obtain a fucoidan solid beverage.

[0018] In some embodiments, the brown algae powder is defatted using 10-15 volumes of ethanol solution.

[0019] Furthermore, the concentration of the ethanol solution is 95%. Furthermore, the degreasing time is 8-12 h, repeated 2-3 times. In some embodiments, the concentration of the CaCl2 solution is 1.5%-2.5%, where % is mass percentage. Furthermore, 10-20 mL of the CaCl2 solution is used for the soaking treatment per gram of brown algae powder.

[0020] Furthermore, the brown algae powder is immersed in the CaCl2 solution at a temperature of 60-70°C for 2-3 h.

[0021] In some embodiments, the alcohol precipitation solution is a 95% ethanol solution.

[0022] Another typical embodiment of the present invention provides a use of the above-mentioned fucoidan solid beverage or the fucoidan solid beverage prepared by the above-mentioned preparation method in the preparation of products for preventing and / or treating Helicobacter pylori infection.

[0023] The present invention will be further described in detail below with reference to specific embodiments. It should be noted that the specific embodiments are intended to explain the present invention rather than to limit it.

[0024] Example 1 A method for preparing a fucoidan solid beverage capable of preventing Helicobacter pylori infection comprises the following steps: (1) Dry the brown algae and crush them to obtain algae powder. Take an appropriate amount of algae powder and defatting it by adding 15 times the volume of 95% ethanol. Stir at room temperature for 12 hours. Repeat three times. After defatting, centrifuge the mixture, collect the precipitate, and air dry.

[0025] (2) Take the defatted algal powder, add 2% CaCl2 solution, with a solid-liquid ratio of 1:15 g / mL, stir at 60-70℃ for 3h, and centrifuge after stirring. Repeat twice and combine the supernatant.

[0026] (3) Concentrate the supernatant, add 4 times the volume of 95% ethanol, precipitate with alcohol, let it stand at 4℃ overnight, centrifuge, and collect the precipitate, which is fucoidan.

[0027] (4) According to the weight ratio, 3 parts of fucoidan, 1 part of resistant dextrin, 1 part of whey protein powder, and 0.000006% of vitamin B12 were mixed and redissolved, homogenized, spray-dried, and directly bagged to obtain a fucoidan solid beverage.

[0028] The following are the component analysis of fucoidan in Example 1 and the activity test results of the fucoidan solid beverage, including the monosaccharide composition analysis and molecular weight analysis of the polysaccharide, and the anti-Helicobacter pylori activity analysis of the fucoidan solid beverage in vivo.

[0029] The results of monosaccharide composition determination showed that fucoidan was mainly composed of fucose, and also contained a small amount of galactose, mannose, glucuronic acid, and xylose, with a molar ratio of 57:7.0:7.0:15:15 (moL%) and a molecular weight of approximately 40 kDa.

[0030] Culture of Helicobacter pylori: Helicobacter pylori was revived in Columbia blood agar medium containing 7% defibrinated sheep blood and cultured in a three-gas incubator (5% O2, 10% CO2, 85% N2).

[0031] In vivo anti-Helicobacter pylori activity assay of a fucoidan solid beverage: Clean-grade KM mice, weighing approximately 20 g, were adaptively housed for 7 days and randomly divided into three groups of five. The blank control group received sterile water orally; the model group received an H. pylori suspension orally until model establishment was achieved; and the fucoidan solid beverage group received the fucoidan solid beverage solution for one week, followed by the solid beverage and then H. pylori orally. At the end of the experiment, the mice were sacrificed, and their entire stomachs were removed under sterile conditions.

[0032] The entire stomach of the mouse was opened along the greater curvature, and the gastric contents were washed with sterile saline. Two gastric tissue samples were collected for subsequent experiments: 1) HE staining of antral tissue; and 2) Giemsa staining of antral tissue. Staining and scoring were performed. The HE staining scoring criteria are shown in Table 1. Giemsa staining scores were based on the following criteria: 3 points for extensive H. pylori colonization; 2 points for moderate H. pylori colonization; 1 point for minimal H. pylori colonization; and 0 points for no H. pylori colonization.

[0033] Table 1 Gastric mucosal histopathological scoring (HE staining)

[0034] HE staining scores of mouse gastric tissue Figure 1 As shown, the model group scored higher, indicating that Helicobacter pylori infection caused gastric inflammation. Compared with the model group, the score of the fucoidan solid beverage group was significantly lower, indicating that the gastric inflammation caused by Helicobacter pylori infection was significantly alleviated after intervention with the fucoidan solid beverage.

[0035] Giemsa staining scores of mouse gastric tissue Figure 2 As shown, the model group scored higher, indicating that the model group had a large number of Helicobacter pylori colonization, and the Helicobacter pylori colonization in the fucoidan solid beverage group was significantly reduced, indicating that fucoidan solid beverage can eliminate Helicobacter pylori and reduce the colonization amount.

[0036] In summary, the fucoidan solid beverage provided by the present invention can reduce the gastric inflammatory response and the amount of Helicobacter pylori colonization during Helicobacter pylori infection in the body, that is, the fucoidan solid beverage obtained by the present invention has a preventive effect on Helicobacter pylori infection.

[0037] The foregoing description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Those skilled in the art will readily appreciate that various modifications and variations of the present invention are possible. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present invention are intended to be within the scope of protection of the present invention.

Claims

1. A fucoidan solid beverage for preventing Helicobacter pylori infection, characterized in that: Includes fucoidan, whey protein, resistant dextrin and vitamin B12; The fucoidan includes fucose, galactose, mannose, glucuronic acid and xylose in a molar ratio of 57:7.0:7.0:15:15, mol%, and a molecular weight of 38-42 kDa.

2. A method for preparing the fucoidan solid beverage according to claim 1, characterized in that: include: S1. After degreasing the brown algae powder with 10-15 times the volume of ethanol solution, the precipitate was collected and dried; S2. Add 1.5%-2.5% CaCl2 solution to the defatted brown algae powder, stir at 60°C for 2-3 hours, separate the solid and liquid, collect the supernatant, concentrate the supernatant, precipitate with alcohol, and collect the precipitate to obtain fucoidan; The material-liquid ratio of brown algae powder to CaCl2 solution is 1g:10-20 mL; S3. Mix the raw materials according to the weight ratio of 3 parts of fucoidan, 1 part of resistant dextrin, 1 part of whey protein powder, and 0.000006% of vitamin B12, redissolve and homogenize, then spray-dry and directly bag to obtain a fucoidan solid beverage.

3. Use of the fucoidan solid beverage according to claim 1 or the fucoidan solid beverage prepared by the preparation method according to claim 2 in preparing products for preventing and / or treating Helicobacter pylori infection.

Images